Equities research analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of NASDAQ PULM opened at $2.12 on Tuesday. The stock’s fifty day moving average price is $2.03 and its two-hundred day moving average price is $1.92. Pulmatrix has a one year low of $1.55 and a one year high of $2.73. The firm has a market cap of $7.74 million, a price-to-earnings ratio of -0.88 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.23 EPS for the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%. The firm had revenue of $5.89 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- Golden Cross Stocks: Pattern, Examples and Charts
- What Are Bonds? A High-Level Overview
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- Stock Analyst Ratings and Canadian Analyst Ratings
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
